Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
Quiz|Articles|November 8, 2023
AD Management in a New Lifestyle Transition
Author(s)Lauren Buchanan, MA, Managing Editor
New lifestyle transitions can affect a patient's treatment adherence and support network. How would you help this new college student?
Advertisement
Lucy just celebrated her 19th birthday and is looking forward to starting her freshman year at Derm State University in 3 weeks. She is excited to live independently in a new state. Lucy’s mother is concerned about her moderate atopic dermatitis (AD), allergy, and asthma treatment regimens in a new environment with a new, unpredictable schedule.
What would you consider in Lucy's treatment plan going forward?
Advertisement
Related to this article
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
Beyond Dry Skin: Rethinking Common Eczema Misconceptions
3
FAQ: Remibrutinib (Rhapsido) Becomes First FDA-Approved Treatment for a Chronic Inducible Urticaria
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5